Aaron Ritter, MD

Appointed
2016

Education & Fellowships

Fellowship - Cleveland Clinic Lou Ruvo Center for Brain Health
Behavioral Neurology and Neuropsychiatry
Las Vegas, NV USA
2016

Fellowship - Behavioral Neurology Neuropsychiatry

2016

Residency - University of Arizona Medical Center
Psychiatry
Tucson, AZ USA
2014

Residency - University of Arizona Medical Center
Pediatrics
Tucson, AZ USA
2011

Medical School - University of Colorado School of Medicine
Denver, CO USA
2010

Undergraduate - University of Wisconsin
Madison, WI USA
2004

Additional Training

• Fellowship in Behavioral Neurology and Neuropsychiatry
  
  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas NV
  
  7/2014-6/2016

  Residency in Psychiatry
  
  University of Arizona, Tucson, AZ
  
  7/2011-6/2014

  Internship
  
  University of Arizona, Tucson, AZ
  
  7/2010-6/2011

  Medical Degree
  
  University of Colorado School of Medicine, Denver, Colorado
  
  8/2006-6/2010

  Bachelor of Arts
  
  University of Wisconsin, Madison, Wisconsin
  
  9/2001-12/2004
  
  

Professional Highlights

• Publications

  RitterA, Banks, SA, Leger, G, Miller, J, Neuropsychologicaltesting in pathologically verified Alzheimer’s disease and frontotemporaldementia: How well do the Uniform Data Set measures differentiate betweendiseases? Alzheimer’s Disease and Associated Disorders. (accepted)

  RitterA, Cummings JL, Fluid Biomarkers inClinical Trials of Alzheimer's Disease Therapeutics. Front Neurol.2015 Aug 31;6:186.

  RitterA, Pillai JA, Treatment of VascularCognitive Impairment. Curr Treat Options Neurol. 2015 Aug;17(8):367.

  Research/Clinical Trials

  PrimaryInvestigator, Clinical and Translational Research Core (CTRC) for Center forBiomedical Research Excellence (COBRE).  National Institute of Health.Cleveland Clinic, Las Vegas, NV.

  Sub-Investigator,A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab inSubjects with Early Alzheimer’s Disease. Cleveland Clinic, Las Vegas, NV.

  Sub-Investigator,A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled,Cross-over Study to Assess the Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition in Patients with Neurodegenerative Disorders.Avanir Pharmaceuticals Inc. Cleveland Clinic, Las Vegas, NV.

  Sub-Investigator,Rasagiline Rescue in Alzheimer’s DiseaseClinical Trial. Alzheimer’s Disease Cooperative Study.  ClevelandClinic, Las Vegas, NV.

  Sub-Investigator,Biomarker Qualification for Risk of MCIdue to AD and Safety and Efficacy Evaluation of Pioglitazone (AD-4833 SR 0.8 mgQD) in Delaying its Onset. Takeda Pharmaceuticals. Cleveland Clinic, LasVegas, NV.

  Sub-Investigator,Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease, Lily. Cleveland Clinic, Las Vegas, NV.

  Sub-Investigator,A Randomized Controlled Trial ofCognitive Remediation and D-cycloserine for Individuals with Bipolar Disorder(DCS). University of Arizona, Tucson, AZ.

Awards & Honors

• Cleveland Clinic Excellence in Teaching Award for 2015-2016

  Cleveland Clinic

  Cleveland Clinic Excellence in Teaching Award for 2014-2015

  Cleveland Clinic

  Ely Lily Research Award for 2013-2014

  University of Arizona

  GME Resident Excellence and Leadership Scholarship for 2012-2013

  University of Arizona, Tucson, Arizona

  Junior Resident Award for Best Overall Performance for 2012-2013

  Department of Psychiatry, University of Arizona

  Dean’s List in Excellence in Teaching by a Houseofficer 2010-2011

  University of Arizona College of Medicine

Memberships

• American Academy of Neurology
• American Neuropsychiatric Association
• International Neuropsychological Society
• International Parkinson and Movement Disorder Society

See publications for Aaron Ritter, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 9/30/2017, Dr. Ritter has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.